

ASX ANNOUNCEMENT

30 September 2024

Annual Report Differences to Appendix 4E

Sydney, Australia – 30 September 2024: Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) refers to the Company’s Appendix 4E for the year ended 30 June 2024 announced on 30 August 2024 and lodgement today of the Company’s Annual Report for the year ended 30 June 2024.

After the Appendix 4E was released, the audit was completed where the following adjustments were identified in the financial statements, and are set out below pursuant to Listing Rule 4.3D:

1. Increase in accrued revenue and contract assets of \$195,742.
2. Foreign exchange differences on intercompany loans of \$316,921 recognised as foreign exchange gain rather than in reserves.
3. \$50,687 transferred from share-based payment reserve to accumulated losses.
4. \$35,341 adjustment to VAT taxes paid in Germany on purchases reducing receivables and increasing other administrative expenses.
5. Lease finance costs of \$3,381 reallocated from administrative expenses to finance costs.
6. The research and development tax incentive receivable and other income decreased by \$85,721.
7. Work-in-progress costs of \$197,060 for the Macquarie Park facility increased plant and equipment and reduced consulting, finance and legal expense.
8. Additional work-in-progress costs for the Macquarie Park facility increased plant and equipment by \$79,860, increased trade and other payables by \$87,846 and increased trade and other receivables by \$7,986.
9. Additional raw material costs of \$127,042 increased trade and other payables and raw materials and consumables expense.

The impact of the above adjustments on the Statement of Financial Position and Statement of Profit or Loss is set out in the tables below.

Impact on Statement of Financial Position

Adjustment number	Line item on statement of financial position	Amount per appendix 4E \$	Adjustment \$	Amount per annual report \$
1	Contract assets	-	195,742	195,742
2,3	Reserves	7,689,853	(266,234)	7,423,619
4,6,8	Trade and other receivables	1,352,934	(113,076)	1,239,858
7,8	Plant and equipment	80,377	276,920	357,297
8,9	Trade and other payables	1,614,328	214,888	1,829,216
Impact of all adjustments to total equity			<u>308,240</u>	

Impact on Statement of Profit or Loss and Other Comprehensive Income

Adjustment number	Line item on statement of profit or loss and other comprehensive income	Amount per appendix 4E \$	Adjustment \$	Amount per annual report \$
1	Revenue	320,890	195,742	516,632
2	Net foreign exchange gain/(loss)	(308,965)	316,921	7,956
4,5	Other administrative expenses	(1,647,974)	(31,960)	(1,679,934)
5	Finance costs	(563)	(3381)	(3944)
6	Other income	1,134,472	(85,721)	1,048,751
7	Consulting, finance and legal expenses	(2,616,985)	197,060	(2,419,925)
9	Raw materials and consumables used	(1,382,709)	(127,042)	(1,509,751)
Impact of all adjustments to profit or loss			<u>461,619</u>	

This announcement has been authorised by the Board.

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Christian Dal Cin CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699
--	--	---

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References: 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>